DGP

US monetary policy is more powerful in low economic growth regimes

Retrieved on: 
Mardi, avril 2, 2024
Tao, Research Papers in Economics, Excess, American Economic Journal, Doan, Policy, RT, Interpolation, Economic growth, Absorption, Business, E32, Low, Browning, European Economic Review, UST, NBER, Forecasting, Macroeconomics, European Economic Association, Journal of Monetary Economics, Journal of Applied Econometrics, TVAR, Oxford University Press, Time series, Economic Inquiry, Paper, Linearity, Joshua Angrist, Nobuhiro, Environment, Political economy, Journal of Financial Economics, Rated R, R2, Website, Emi, Energy economics, Probability, Medical classification, Eurozone, Sigismund, Quarterly Journal of Economics, Zero lower bound, History, Nature, Chapter, ZT, Journal of Political Economy, Bocconi University, OLS, Statistics, University of California, Irvine, PDF, Classification, ECB, XS, ITP, Impact, Estimation, DGP, Mark Thoma, Social science, Elsevier, JEL, Cambridge University Press, Real, M1, Research, Textbook, Private sector, FED, Credit, UTT, Literature, Federal Reserve, Knotek, Evelyn Regner, Table, European Central Bank, Chow, FRED, Monetary economics, Wald, Ben Bernanke, Premium, P500, BIS, EWMA, International Economic Review, Federal funds rate, Money, Treasury, C32, The Economic Journal, Federal Reserve Economic Data, Employment, Risk, FFR, Suggestion, FOMC, Monte Carlo method, Sigmoid, VAR, Database, Projection, Ascari, The Journal of Finance, Yield curve, United States Treasury security, Economy, Fed, Figure, NFCI, Financial economics, EXP, Freedom, Central bank, PCE, Monetary policy, American Economic Review, Exercise, Interest, Samuel, URR, Rigidity, Business cycle, XT, Landing slot, Chap, Daron Acemoglu, Markov, Blue chip, Kuttner, Response, Quarterly Journal, YT, Channel, GDP, Standard, Effect, Federal, Cost, Christian Social Union (UK), Journal of Econometrics, Comm, Mark Gertler, Use, Economic statistics, IW, Bank for International Settlements, Finance Secretary (India), UC, Bank, Reproduction, Section, News, Housing, Data, Food industry
Key Points: 

    MatSing Lens Antennas Deployed to Deliver Enhanced Network Capacity at the Allegiant Stadium in Las Vegas

    Retrieved on: 
    Jeudi, février 8, 2024
    Mobile, Wireless, Sports, Internet, Hardware, Data Management, Technology, Football, 5G, Satellite, Audio, Video, Other Technology, Telecommunications, DAS, DGP, Allegiant Stadium, Multimedia

    MatSing , the pioneer and innovator of high-capacity lens antenna technology, today announced increased coverage and capacity at the Allegiant Stadium with the deployment of 30 multibeam lens antennas to add to the 30 lens antennas already deployed at the venue.

    Key Points: 
    • MatSing , the pioneer and innovator of high-capacity lens antenna technology, today announced increased coverage and capacity at the Allegiant Stadium with the deployment of 30 multibeam lens antennas to add to the 30 lens antennas already deployed at the venue.
    • (Photo: Business Wire)
      “MatSing lens antennas ideally serve our needs for a multi-carrier neutral host distributed antenna system (DAS) network at Allegiant Stadium,” Steve Dutto, DGP President, added.
    • Additionally, we deployed 14 MatSing lens antennas to cover several parking lots for all carriers.
    • As MatSing continues to support Allegiant Stadium and DGP, fans and patrons are sure to experience game days and events like never before.

    Fingerprint Drug Test Delivers Quantifiable Benefits for Customers as Adoption in Workplaces Accelerates

    Retrieved on: 
    Mardi, janvier 30, 2024
    Well, Auctus, Intelligence, DGP, Overalls, P&O Ferries, Urine, Workplace, HR, Organization, Medical device

    NEW YORK, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today reported on the key operational benefits that customers are experiencing following deployment of the Intelligent Fingerprinting Drug Screening System to support workplace drug testing.

    Key Points: 
    • “We’re seeing an increasing need for drug and alcohol testing across major construction and manufacturing projects.
    • Well-supported employee inductions on one of Europe’s largest construction sites: Auctus Management Group has implemented a streamlined induction process utilizing the Intelligent Fingerprinting Drug Screening System at its core.
    • DGP has effectively minimized on-site disruption caused by half-day absences required for urine-based testing by switching to quick, on-site fingerprint sweat-based drug screening in minutes.
    • Achieved greater control through in-house management of drug testing: Independent chemical manufacturer Robinson Brothers found that replacing its external urine-based drug testing service with the Intelligent Fingerprinting Drug Screening System meant it could conduct the same volume of workplace drug screening at around half the cost.

    DGP Plc Takes Drug Testing In-house with Fingerprint Sweat-based Testing

    Retrieved on: 
    Lundi, janvier 22, 2024
    Organization, DGP, Intelligence, Medical device

    NEW YORK, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that DGP Plc has selected the revolutionary portable Intelligent Fingerprinting Drug Screening System to enable in-house drug testing.

    Key Points: 
    • The company implements robust processes and risk-based SHEQ management to support the way it delivers its works, and will now use the Intelligent Fingerprinting Drug Screening System to enable faster, more convenient and more flexible workplace drug testing.
    • “Having already seen fingerprint sweat-based drug screening in action at another company, I knew that the Intelligent Fingerprinting would work well for DGP,” explained Ruth Trant, DGP Plc’s SHEQ & Assurance Director.
    • With fingerprint sweat-based testing we can conduct the ten-minute tests there and then, with people not having to wait.
    • “Our system’s flexibility and ease of use makes it much simpler for organizations like DGP to manage workplace drug testing internally, resulting in overall cost savings and improved productivity due to minimal disruption.”

    AFL Acquires Forza Telecom, Enhancing its Position in Wireless Markets for Major Sports Venues

    Retrieved on: 
    Mercredi, janvier 3, 2024
    Networks, Hardware, Manufacturing, Technology, Engineering, DAS, Multimedia, Acquisition, AFL, DGP, Forza, Sport, OTS, Mobile phone

    View the full release here: https://www.businesswire.com/news/home/20240103436764/en/

    Key Points: 
    • View the full release here: https://www.businesswire.com/news/home/20240103436764/en/
      AFL Acquires Forza Telecom, Enhancing its Position in Wireless Markets for Major Sports Venues (Photo: Business Wire)
      Founded in 2010, Forza Telecom has distinguished itself as a provider of state-of-the-art DAS installations to some of the largest sports venues in North America.
    • The acquisition will strengthen AFL's U.S. Services' existing position in wireless networking for U.S. sports venues in the West and Southwest while also expanding Forza Telecom's presence in the Southeast region.
    • In addition, AFL enhances Forza Telecom's capabilities in complex RF design, large-scale installation, ongoing monitoring and maintenance services.
    • "With the addition of Forza Telecom to AFL's wireless service portfolio of Beam Wireless and Optical Telecom (OTS), AFL is elevating our position and enhancing our service offering in the DAS wireless market," explained Seneca Mullins, President of AFL's U.S. Services.

    Evoke Pharma & EVERSANA Unveil Cost Savings Real-World Data Demonstrating Meaningfully Reduced Healthcare Costs for Patients Using GIMOTI Over Oral Metoclopramide Presented at the American College of Gastroenterology 2023

    Retrieved on: 
    Mardi, octobre 31, 2023
    IH, NMCP, Patient, Bloating, FDA, Abdominal pain, DGP, Research, American College, Martin PBM Mariner, Stomach, Metoclopramide, Vomiting, ACG, Ensuring Patient Access and Effective Drug Enforcement Act, News, Diabetes, Conditional sentence, American College of Gastroenterology, Texas Tech University, Nausea, Gastroparesis, ED, HO, UC San Diego Health, Comparison, Pharmacy, Annual general meeting, Cleveland Clinic, Hospital, IBM, Associate, DDW, LHT, Pharmaceutical industry, Medicine

    The data describes the results of a comparative study that highlights cost-related healthcare resource utilization data (HCRU) in DGP patients taking GIMOTI (nasal metoclopramide) versus those on oral metoclopramide over a six-month period.

    Key Points: 
    • The data describes the results of a comparative study that highlights cost-related healthcare resource utilization data (HCRU) in DGP patients taking GIMOTI (nasal metoclopramide) versus those on oral metoclopramide over a six-month period.
    • HCRU is the description and quantification of patients’ total usage of healthcare services such as emergency department (ED) visits, hospitalization or how often they visit a healthcare provider in the office.
    • The cost to the patients and the healthcare system is significant and the impact is considerable for all parties involved.
    • The data for GIMOTI continues to reinforce those providers can and should strive to improve outcomes for patients,” commented Chris Quesenberry, GIMOTI Chief Commercial Officer.

    Evoke Pharma’s Abstract Entitled “Superiority of Nasal Spray Compared to Orally Administered Metoclopramide in Reducing Healthcare Costs in Treating Diabetic Gastroparesis Patients” to Be Presented at The American College of Gastroenterology (ACG) 2023 An

    Retrieved on: 
    Mercredi, octobre 18, 2023
    Patient, Abdominal pain, DGP, Standard of care, American College, Stomach, ACG, University of California, Diabetes, American College of Gastroenterology, Texas Tech University Health Sciences Center El Paso, Gastroparesis, Nausea, GERD, Metoclopramide, Evoke, University, Ondansetron, ER, Cleveland Clinic, DDW, Pharmaceutical industry, MD

    These new data build upon the findings presented in plenary session at Digestive Disease Week (DDW) earlier this year which demonstrated significant reductions in healthcare resource utilization (e.g., office, emergency department (ER) and hospital visits, etc.).

    Key Points: 
    • These new data build upon the findings presented in plenary session at Digestive Disease Week (DDW) earlier this year which demonstrated significant reductions in healthcare resource utilization (e.g., office, emergency department (ER) and hospital visits, etc.).
    • Upon identifying a major gap in gastroparesis treatment, Evoke developed GIMOTI as a nasal spray to specifically by-pass erratic absorption issues that DGP patients often suffer with medications that are in tablet or pill form.
    • Patients with long-standing diabetes can develop gastroparesis (a delay in stomach emptying).
    • “With the lack of effective oral treatments, and the promising findings for GIMOTI, Evoke is dedicated to make GIMOTI the standard of care for patients with diabetic gastroparesis,” said Dave Gonyer, R.Ph., Evoke Pharma CEO.

    Evoke Pharma and EVERSANA Announce Abstract Selection for Plenary Oral Presentation at The American College of Gastroenterology (ACG) 2023 Annual Meeting

    Retrieved on: 
    Mardi, juillet 25, 2023
    Real, ER, Cleveland Clinic, University, Metoclopramide, Gastroenterology, DRS, University of California, DDW, Gastroparesis, Patient, DGP, Diagnosis, American College of Gastroenterology, American College, FDA, Texas Tech University Health Sciences Center El Paso, ACG, Disease, Pharmaceutical industry

    During the meeting, the authors of the abstract, including Drs.

    Key Points: 
    • During the meeting, the authors of the abstract, including Drs.
    • Recent Real World Outcomes data, presented at DDW in May, demonstrated Gimoti significantly reduced healthcare resource utilization (i.e., ER visits or hospitalizations) compared to oral metoclopramide.
    • This new data builds off those findings and explore the potential to reduce the cost of care for patients with DGP.
    • “The ACG is the preeminent professional organization that champions the prevention, diagnosis, and treatment of digestive disorders, including DGP.

    Real-World Data Presented by Evoke Pharma and EVERSANA at Digestive Disease Week 2023 Shows Gimoti® Meaningfully Reduces Utilization of Healthcare Resources

    Retrieved on: 
    Mardi, mai 9, 2023
    Gastroparesis, Insurance, Hospital, University Challenge 2013–14, UC San Diego Health, Absorption, Abdominal pain, Associate, Index, Vomiting, DDW, NCMP, Patient, Physician, DGP, Nausea, Bloating, Metoclopramide, ED, GI, Female, NMCP, Pharmaceutical industry

    HCRU is the description and quantification of patients’ total usage of healthcare services such as hospitalization or how often they visit their physician in office.

    Key Points: 
    • HCRU is the description and quantification of patients’ total usage of healthcare services such as hospitalization or how often they visit their physician in office.
    • Similarly, for inpatient hospitalizations and emergency department visits the likelihood was 68% and 60% lower, respectively, for NMCP-treated patients versus OMCP.
    • The positive effects of nasal metoclopramide versus oral metoclopramide on patients and healthcare resources is worth noting and encouraging for the GI motility community.
    • We strongly believe GIMOTI has the potential to be the standard of care for DGP treatment,” commented Matt D’Onofrio, President and COO of Evoke Pharma.

    Evoke Pharma’s Real-World Healthcare Utilization Data Comparing GIMOTI® to Oral Metoclopramide to Be Presented at Digestive Disease Week (DDW) 2023

    Retrieved on: 
    Jeudi, mai 4, 2023
    Flare, University, Gastroenterology, McCormick Place, Research, Gastroparesis, Abdominal pain, Associate, Stomach, Vomiting, DDW, MD, Patient, Machine learning, DGP, Nausea, Metoclopramide, FDA, Pharmaceutical industry, Medicine

    SOLANA BEACH, Calif., May 04, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, announced that the abstract entitled “Reducing Real-World Healthcare Resource Utilization For Patients With Diabetic Gastroparesis (DGP) Treated with Metoclopramide Nasal Spray Versus Oral Metoclopramide” will be presented at Digestive Disease Week (DDW) 2023 taking place from May 6-9, 2023 at the McCormick Place, Chicago.

    Key Points: 
    • These real-world data were selected for presentation alongside a total of only six (6) meritorious clinical abstracts from more than 3,500 that were submitted.
    • In addition, Evoke Pharma will showcase their GIMOTI nasal spray and supporting educational materials at DDW booth #3334.
    • AGA Distinguished Plenary Presentation Title: “Reducing Real-World Healthcare Resource Utilization for Patients with Diabetic Gastroparesis (DGP)
      2.
    • Poster Presentation Title: “Use of Machine Learning to Identify Gastroparesis Patient Appropriate for Nasal Spray Metoclopramide” (Poster Number: